5,6-Dimethylxanthenone-4-acetic acid (DMXAA), a novel antivascular agent: phase I clinical and pharmacokinetic study by Rustin, G J S et al.
5,6-Dimethylxanthenone-4-acetic acid (DMXAA), a novel
antivascular agent: phase I clinical and pharmacokinetic study
GJS Rustin*
,1, C Bradley
2, S Galbraith
1, M Stratford
3, P Loadman
4, S Waller
5, K Bellenger
5, L Gumbrell
5,
L Folkes
3 and G Halbert
6 on behalf of the Phase I/II Trials Committee of Cancer Research UK
1Department of Medical Oncology, Mount Vernon Hospital, Northwood, Middlesex HA6 2RN, UK;
2Bradford Royal Infirmary, Bradford BD9 6RJ, UK;
3Gray Cancer Institute Mount Vernon Hospital, Northwood, Middlesex HA6 2JR, UK;
4Cancer Research Unit, University of Bradford, Bradford BD7 1DP,
UK;
5Drug Development Office of Cancer Research UK, PO Box 123, London WC2A 3PX, UK;
6Cancer Research UK Formulation Unit, University of
Strathclyde, Glasgow G1 1XW, UK
The purpose of this phase I, dose-escalation study was to determine the toxicity, maximum tolerated dose, pharmacokinetics, and
pharmacodynamic end points of 5,6-dimethylxanthenone acetic acid (DMXAA). In all, 46 patients received a total of 247 infusions of
DMXAA over 15 dose levels ranging from 6 to 4900mgm
 2. The maximum tolerated dose was established at 3700mgm
 2; dose-
limiting toxicities in the form of urinary incontinence, visual disturbance, and anxiety were observed at the highest dose level
(4900mgm
 2). The pharmacokinetics of DMXAA were dose dependent. Peak concentrations and area under the curve level
increased from 4.8mM and 3.2mMh, respectively, at 6mgm
 2 to 1290mM and 7600mMh at 3700mgm
 2, while clearance declined
from 7.4 to 1.7lh
 1m
 2 over the same dose range. The terminal half-life was 8.174.3h. More than 99% of the drug was protein
bound at doses up to 320mgm
 2; at higher doses the percent free drug increased to a maximum of 6.9% at 4900mgm
 2. Dose-
dependent increases in the serotonin metabolite 5-hydroxyindoleacetic acid were observed at dose levels of 650mgm
 2 and above.
There was one unconfirmed partial response at 1300mgm
 2. In conclusion, DMXAA is a novel vascular targeting agent and is well
tolerated.
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While research interest in cancer therapy that targets tumour
vasculature is currently directed at angiogenesis inhibitors, agents
that interrupt existing tumour vasculature are also under
investigation. The antitumour activity of flavone acetic acid
(FAA) against a range of transplantable murine tumours with
established vasculature is well documented (Plowman et al, 1986;
Smith et al, 1987; Hill et al, 1989) and appears to be related to the
production of tumour necrosis factor-alpha (TNF-a), since
antibodies to TNF can prevent the reduction in blood flow caused
by FAA (Mahadevan et al, 1990). In contrast to its activity in
murine cell lines, FAA does not induce TNF in human mono-
nuclear cell lines (Ching et al, 1994), and species differences in the
target of action are the most likely explanation for the apparent
failure of FAA to demonstrate any significant clinical antitumour
activity.
A research programme at the Auckland Cancer Society Research
Centre (Auckland, New Zealand) directed at synthesising ana-
logues of FAA without a species difference in antitumour activity
resulted in 5,6-dimethylxanthenone acetic acid (DMXAA) (Re-
wcastle et al, 1989, 1991). More active than FAA, and with a 12-fold
higher potency in murine tumour models (Rewcastle et al, 1991),
DMXAA induces TNF production in cell lines from humans, as
well as those from mice. The mechanism of antitumour action of
DMXAA, like that of FAA, differs from that of directly cytotoxic
drugs. 5,6-Dimethylxanthenone acetic acid has selective activity in
targeting tumour vasculature in vivo, producing vascular shut-
down, reducing tumour blood flow, and consequently causing
haemorrhagic necrosis (Zwi et al, 1994b; Laws et al, 1995).
Repeat dosing at 3- or 7-day intervals produced greater
induction of TNF-a and growth delay in colon 38 tumours in
mice than a single dose of DMXAA (Philpott et al, 1995). A single-
and multiple-dose toxicity study was therefore performed on MF1
mice and Wistar rats, which indicated that the dose that was lethal
in 10% (LD10) was 20mgkg
 1 (BIBRA International, Carshalton,
Surrey, UK). The starting dose in humans is based on 10% of this
figure equivalent to 6mgm
 2. The Cancer Research Campaign
(now Cancer Research UK) has conducted two parallel phase I
trials of DMXAA. A single centre study in Auckland, New Zealand
used a 3-weekly schedule (Jameson et al, submitted). A two-centre
UK study, at Mount Vernon Hospital, Northwood and Bradford
Royal Infirmary, Bradford, used a weekly schedule and is the
subject of this report. The primary objectives of this study were to:
(1) determine the toxicity profile of DMXAA, (2) establish the
maximum tolerated dose (MTD), (3) characterise the pharmaco-
kinetic profile, and (4) determine the effects of DMXAA on
coagulation factors and the production of TNF-a, nitric oxide, and
serotonin. A secondary aim was to assess the antitumour efficacy
of DMXAA. Dynamic contrast enhanced magnetic resonance
imaging (DCE-MRI) studies to assess the effect of DMXAA on
human tumour vasculature were incorporated into the two phase I
trials by a protocol amendment and the results of these studies are
reported in full separately (Galbraith et al, 2002). Received 24 July 2002; revised 8 January 2003; accepted 22 January 2003
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lPATIENTS AND METHODS
Eligibility
Male or female patients aged 18–75 years with histologically
confirmed cancer not amenable to standard curative therapy or
refractory to conventional therapy were eligible for inclusion in
this study. Other eligibility criteria included documented disease
progression within 2 months prior to entry into the study, a World
Health Organisation (WHO) performance status of 0–2, a life
expectancy of 43 months, and adequate bone marrow, hepatic,
and renal function. Patients who had previously received antic-
ancer therapy were eligible if at least 4 weeks had elapsed since
completion of that therapy (6 weeks for nitrosoureas and
mitomycin C). Patients were excluded from the study if they had
concurrent malignancies, or if they had experienced any other
serious medical conditions, uncontrolled or serious infection in
the 28 days prior to the study. Women who were capable of child
bearing were required to use effective contraceptive methods. The
local ethics committees approved the study, and all patients gave
written informed consent prior to participation in the study.
Study design
5,6-Dimethylxanthenone acetic acid was formulated as a
20-mgml
 1 solution in 0.1 M phosphate buffer at pH 7.7 in amber
glass vials and stored at room temperature. During the study, the
formulation was changed to 100mgml
 1 in 0.02 M phosphate
buffer at pH 7.9 to accommodate higher doses while minimising
infusion volume. Patients treated at 3700 and 4900mgm
 2
received the 100mgml
 1 formulation.
5,6-Dimethylxanthenone acetic acid was administered as a 20-
min intravenous infusion via a peripheral vein in a once-weekly
schedule. The starting dose of DMXAA was 6mgm
 2 and dose
escalation was planned to follow a modified Fibonacci scheme
subject to toxicity and pharmacokinetic data. It was planned that if
DMXAA area under the curve (AUC) levels were lower than
expected from the animal data, then dose escalation would be
accelerated. Three patients were entered at each dose level and two
patients had to be followed for at least 3 weeks before any patients
could be entered at the next level. If any of the following toxicities
occurred, three additional patients were to be entered: 4Grade 2
neutropenia, mucositis, diarrhoea, alanine aminotransferase serum
(ALT), aspartate aminotransferase serum (AST), renal toxicity,
vomiting that did not respond to symptomatic treatment, 4Grade
1 thrombocytopenia, neurological or cardiac toxicity, or an
increase of one grade of peripheral neuropathy, if present at
baseline. Where specific toxicities were not considered to be drug
related, dose escalation was continued without expanding the dose
level.
Before treatment and once weekly during the study, patients
were given a physical assessment (including WHO performance
status), and routine laboratory tests including full blood count
(FBC) with differential, international normalised ratio (INR),
activated partial thromboplastin time (APTT), and urine analysis
were performed. Full blood count was repeated 24 and 72h after
the first infusion and 24h after the fourth infusion. An
electrocardiogram (ECG) was performed before treatment and at
the end of the study. During treatment, blood pressure and pulse
were taken at 5 and 15min during the infusion, at the end of the
infusion, and at 30-min intervals from the end of the infusion, for
at least 6h.
The National Cancer Institute of Canada Clinical Trials Group
(NCIC-CTG) Expanded Common Toxicity Criteria (CTC) were
used to assess adverse events and their severity. Dose-limiting
toxicity (DLT) was defined as Grade 2 neurotoxicity, Grade 3 for
other nonhaematological toxicity (excluding alopecia and nausea),
or Grade 4 haematological toxicity, which lasted more than 4 days
or was associated with fever or bleeding. The MTD was defined as
the dose below that at which more than 30% of the patient
population experienced unacceptable toxicity caused by DMXAA.
One course of treatment consisted of six once-weekly infusions
of DMXAA. If tumour response was observed or patients were
benefiting from treatment, they could receive a maximum of two
courses, otherwise they came off study after one course.
Disease measurements (CT scan or chest X-ray) were made at
baseline and week 6 to assess response and again after 12 weeks if
the patient remained on study. Response criteria were those
produced by the WHO.
Pharmacokinetic studies
Blood samples (7ml) were collected into heparinised tubes
immediately before the start of the infusion, immediately before
the end of the infusion (t¼0), and at 0.25, 0.5, 0.75, 1, 1.5, 2, 4, 8,
12, and 24h after the end of the infusion for the first dose of
DMXAA. Following subsequent infusions in the same patient,
samples were taken before treatment, immediately before the end
of the infusion, and at 4h after the end of treatment. The blood was
centrifuged at 1500g for 10min and aliquots of plasma were stored
at  201C. Plasma concentrations of DMXAA were determined
using high-performance liquid chromatography (HPLC) with
fluorescence detection. As a result of the almost three orders of
magnitude dose range, exact amounts of sample and internal
standard (i.s.) varied according to the expected concentration
range, but typically to 100ml plasma was added 50ml i.s.
(5-propoxyxanthenone acetic acid, 100nmolml
 1), the sample
was mixed, and 300ml acetonitrile:methanol (3:1 vv
 1) added.
After again mixing, the protein precipitate was removed by
centrifugation (12000g, 1min), and the supernatant dried in a
centrifugal evaporator (Hetovac). The samples were reconstituted
in 120ml HPLC starting eluent and transferred to HPLC vials for
injection. For samples from doses above 1000mgm
 2, the drying
stage was omitted. The assay was validated using control human
plasma spiked with known amounts of DMXAA, and found to be
linear from 50nM to 2mM. Intra- and interassay recovery was
between 102 and 104% and CV ranged from 0.2% at 20mM to 1.9%
at 500mM.
Free plasma DMXAA concentrations were determined by
ultrafiltration. Samples of plasma (300ml) were added to Amicon
Centrifree YM-30 filters, centrifuged at room temperature (2000g,
20min), and the resultant filtrate analysed without further
processing by HPLC.
Separation of DMXAA from its metabolites and the i.s. was
achieved using a linear gradient. The column was a Lichrospher
RP18e cartridge (125 4mm, Merck, Aston Scientific Stoke
Mandeville, UK), fitted with a guard column (4 4mm) packed
with the same material. Eluents comprised (A) 2% (vv
 1) acetic
acid (HiPerSolv, Merck, Aston Scientific Stoke Mandeville, UK)
and (B) acetonitrile:water (3:1 vv
 1), and the gradient was run
from 35 to 62% B over 9min, then increased to 80% over 0.5min,
and held there for 3min before returning to the starting
conditions. For free drug determinations, only the first stage of
the gradient was required. The flow rate was 1.6mlmin
 1.
Detection was by fluorescence using a Waters 474 detector fitted
with a 5ml flow cell, with excitation at 345nm, emission 409nm.
Samples were injected using a Waters 717 autosampler, and data
were collected and processed using Waters Millennium software.
Guard columns were changed every B200 analyses.
Pharmacokinetic data were fitted using nonlinear least-squares
analysis, with statistical weighting inversely proportional to
concentration
2, to a mono-, bi-, or tri-exponential elimination
function using a computer-based fitting program (Microcal Origin,
Aston Scientific Stoke Mandeville, UK). The most appropriate
function was chosen by minimising Akaike’s information criterion
(AIC) (Yamaoka et al, 1978). The AUC was calculated using the
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ltrapezoid method to give the value to 24h, then extrapolating to
infinity by adding C24h/kel. Clearance was calculated as dose/AUC.
Pharmacodynamic studies
Blood samples for the determination of nitrate and TNF-a were
collected as outlined in the pharmacokinetics section and were
stored at  20 and  701C for nitrate and TNF-a, respectively.
Additional samples for 5-hydroxyindoleacetic acid (5-HIAA)
determination were taken pretreatment and at 1, 4, 8, and 24h
postinfusion. Samples were stored at  701C. Plasma concentra-
tions of nitrate were determined by ion-exchange chromatography
with absorbance detection (Stratford, 1999). Nitrate is the end
product of nitric oxide synthesis, and is raised in mice after
treatment with DMXAA (Thomsen et al, 1991; Moilanen et al,
1998). Plasma TNF-a concentrations were determined using a
commercially available ELISA kit (Genzyme). Serotonin mediates
the effect of TNF-a and has been shown to be important in the
action of DMXAA (Baguley et al, 1993). Its metabolite 5-HIAA was
measured as serotonin is too unstable. Concentrations of 5-HIAA
in plasma were determined by HPLC with electrochemical
detection (Kestell et al, 2001).
By a protocol amendment, DCE-MRI scans were performed on
patients treated with DMXAA at doses of 500mgm
 2 or higher
and are reported separately (Galbraith et al, 2002).
RESULTS
Patient characteristics
In total, 46 patients were recruited to the study. All but one had
undergone one or more surgical procedures. Their baseline
characteristics and prior therapy are summarised in Table 1.
All patients were included in the analysis of the toxicity of
DMXAA and in the pharmacokinetic and pharmacodynamic
evaluations; however, 10 patients were excluded from the
assessment of response, including one patient who was excluded
because she continued to take tamoxifen therapy. The 46 patients
in the study received a total of 247 infusions of DMXAA, a median
of six infusions per patient (range 1–11), given once weekly. One
patient, treated at 650mgm
 2, was retreated as a new patient at
2300mgm
 2.
Table 2 presents the dose-escalation schedule, with the number
of patients treated at each dose level, and the number of infusions
of DMXAA they received.
The dose of DMXAA was escalated from 6 to 4900mgm
 2 in 15
dose levels. The first escalation in dose (1.7-fold increase) was
carried out in line with the planned modified Fibonacci scheme. As
plasma AUC values at the first dose level were lower than predicted
for DMXAA, subsequent dose escalation was guided by a
combination of toxicity and pharmacokinetic data, both from this
study and the parallel phase I study in New Zealand (Jameson et al,
submitted). There were five successive dose escalations that
doubled the dose of DMXAA; further dose escalations increased
the dose by factors of 1.3–1.6.
Toxicity
After the fifth patient (treated at 10.2mgm
 2) became delirious
following the fifth and sixth infusions of DMXAA, the protocol was
amended to increase the number of patients at each dose level to
four in order to obtain information about the cumulative toxicity
of DMXAA. As no further cumulative toxicities were observed in
the next 13 patients (10.2–81.6mgm
 2), the amendment was
cancelled and the number of patients at each dose level returned to
three.
The MTD was established at 3700mgm
 2 with three patients in
the UK and seven patients in New Zealand receiving this dose. One
patient with ovarian cancer was treated at the highest dose level
(4900mgm
 2) when DLT was observed; the patient experienced
Grade 3 urinary incontinence, Grade 2 visual disturbance, and
Grade 2 anxiety. It was considered unethical to treat any more
patients at 4900mgm
 2 as all three patients treated in New
Zealand at that dose experienced DLT (MB Jamieson, personal
communication). This consisted of one or more of tremor, feeling
light-head and restless, urinary incontinence, Grade 2 visual
disturbance anxiety, slurred speech, confusion and expressive
dysphasia, and in one case breathlessness and left ventricular
failure. Table 3 presents the most frequently reported toxicities
Table 1 Patient characteristics and prior therapy
Characteristic Patients (n)
No. of patients (M/F) 46 (23/23)
Mean age (range) in years 58 (34–77)
WHO performance status
01 3
12 9
24
Tumour types
Colon/rectum 9
Kidney 8
Ovary 7
Unknown primary 7
Melanoma 4
Soft tissue sarcoma 3
Carcinoid/small bowel 2
Uterus 2
Breast 1
Lung 1
Oesophagus 1
Pancreas 1
Renal pelvis 1
Prior therapy
Radiotherapy 12
Biotherapy/hormone 11
Chemotherapy 35
Table 2 Dose-escalation schedule
Dose level (mgm
 2) Patients per dose level (n) Infusions (n)
63 1 5
10.2 3 21
20.4 4
a 18
40.8 4
a 23
81.6 4
a 24
160 3 18
320 3 17
500 3 12
650 3 17
1000 3 15
1300 3 16
1750 3 11
2300 3 18
3700 3 21
4900 1 1
aAn amendment to the protocol required that four patients were treated at each
dose level; however, the number of patients at each dose level returned to three
some months later. One patient treated at 650mgm
 2 was retreated as a new
patient at 2300mgm
 2.
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to treatment with DMXAA.
There was no significant haematological toxicity such as
neutropenia related to DMXAA. As expected in patients with
advanced cancer, anaemia (Grades 1 and 2) and lymphocytopenia
(mostly Grade 3) occurred commonly but were judged mostly to be
unrelated to treatment.
The most common toxicities related to treatment were
neurological symptoms, primarily visual disturbance, dizziness/
vertigo, headache, and tumour pain. At dose levels up to and
including 650mgm
 2, some visual disturbance was reported. One
patient with colorectal cancer at a dose level of 6mgm
 2
experienced subtotal loss of vision (Grade 1) and other neurolo-
gical symptoms (Grades 1–3). One patient with uterine cancer
treated at 10.2mgm
 2 had spots before the left eye (Grade 1).
Grade 1 disturbance of colour vision (7blurred or brightness of
vision) was recorded at doses above 650mgm
 2. All patients who
received doses of 1750mgm
 2 or higher experienced Grade 1–2
disturbance of colour vision following each infusion. The median
time to onset was 10min and the median duration 28.5min with
complete recovery. Grade 2 disturbance of colour vision was
reported in one patient at 3700mgm
 2 and one patient at
4900mgm
 2.
Treatment-related tumour pain (Grades 1–3) was reported in 12
patients (26%) at doses of 40.8mgm
 2 and above. At 3700mgm
 2,
one patient who had a total of 11 infusions of DMXAA experienced
warmth/tightness in the tumour following the first, second, and
eighth infusion, starting at 17–44min after the infusion and
lasting for 100–115min. In total, 10 patients (22%) experienced
Grade 1 dizziness/vertigo (including light-headedness) related to
treatment. These symptoms were reported from the first dose level
(6mgm
 2), but were of brief duration (median 15min) and were
not dose limiting.
Nausea (mainly Grade 1) and vomiting (Grades1 or 2) were the
most frequently reported treatment-related gastrointestinal symp-
toms, affecting 21 (46%) and 12 (26%) of the patients, respectively.
These symptoms were reported from the first dose level
(6mgm
 2) but were of brief duration and not dose limiting.
At higher dose levels, the time to onset was more acute,
with nausea or vomiting occurring within minutes at a dose
level of 1750mgm
 2 or higher. Patients who experienced nausea
or vomiting following the first infusion received antiemetics
prior to further infusions, which controlled vomiting but not
nausea.
There were no major cardiovascular effects associated with
DMXAA treatment. Nine patients (20%) experienced Grade 1
drug-related hypertension and Grade 1 drug-related hypotension
was recorded in six patients (13%). Neither hypertension nor
hypotension appeared to be dose dependent.
Malaise was the flu-like symptom most frequently attributed to
treatment, occurring in 12 patients (26%; seven with Grade 1
symptoms). Malaise occurred at all dose levels and was not dose
dependent, cumulative, or dose limiting. Grade 1 or 2 sweating was
attributed to treatment in four patients (9%), with two patients
experiencing the symptom in conjunction with the infusion at
doses of 3700mgm
 2 or above. Seven patients (15%) experienced
either Grade 1 venous irritation or pain at the site of intravenous
injection, related to the infusion of DMXAA.
Pharmacokinetics
There was a progressive change in the pharmacokinetic model with
increase in dose of DMXAA (from a three- to a one-compartment
model, Figure 1). The terminal elimination half-life for all patients
was 8.174.3h.
Peak plasma concentrations measured at the end of infusion
increased from 4.873.1mM at 6mgm
 2 to 12907105mM at
3700mgm
 2. The increase was linear with a slope of unity on a
log–log plot up to 2300mgm
 2, but there was some evidence that
concentrations reached a plateau at the highest two doses of 3700
and 4900mgm
 2, as shown in Figure 2A.
Table 3 Doses at which the most frequently reported drug-related toxicities were seen with DMXAA and their maximum grade per patient
Maximum toxicity grade
6–500mgm
 2 (n=27) 650–1300mgm
 2 (n=9) 1750mgm
 2 (n=3) 2300–4900mgm
 2 (n=7)
Adverse event Grade 1 Grades 2–4 Grade 1 Grades 2–4 Grade 1 Grades 2–4 Grade 1 Grades 2–4
Haematological
Haemoglobin 2 1 2 2 3
Lymphocytes 1 2 1 3 4
PT 1 1 3 1
Nonhaematological
Neurological
Dizziness/vertigo 5 2 5 2
Headache 3 1 1 1
Pain 1 3 3 1 4
Other (inc. visual disturbance) 2 2 3 5 2
Gastrointestinal
Nausea 12 2 1 1 2 1 2
Vomiting 6 1 1 1 1 2
Anorexia 2 2 1 1
Cardiac
Hypertension 3 1 1 4
Hypotension 4 1 1
Flu-like symptoms
Malaise 5 3 1 1 1 1
Dermatological
Local 1 3 4
PT=prothrombin time.
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from 3.2271.49mMh at the lowest dose (6mgm
 2) to 76407
1610mMh at 3700mgm
 2 (Figure 2B).
At the highest dose level (4900mgm
 2), the AUC was
higher than predicted from preclinical studies in the mouse.
This may be in part due to interspecies differences in protein
binding. At doses of up to 320mgm
 2, DMXAA was more
than 99% plasma protein bound. At higher doses, the percentage of
free drug increased, with a mean value of 4.271.4%
above 1000mM. At the two highest doses (3700 and 4900mgm
 2),
the mean free AUC was 2.3170.16% of the total AUC.
The relation between Cmax and percent free drug is shown in
Figure 2C. The nonlinearity of the AUC dose plot resulted
from a gradual decrease in the clearance of DMXAA
from 7.474.2lh
 1m
 2 at 6mgm
 2 to 1.6570.39lh
 1m
 2 at
3700mgm
 2.
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Figure 1 Plasma concentrations of DMXAA after 6, 320, and 4900mgm
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The routes of DMXAA metabolism were initially identified from in
vitro work in human liver microsomes (Webster et al, 1995; Miners
et al, 1997). Several metabolites of DMXAA were identified by
HPLC-MS in plasma from patients in this study, including
6-hydroxymethyl-5-methylxanthenone-4-acetic acid and glucuro-
nides of 6-hydroxymethyl-5-methylxanthenone-4-acetic acid and
the parent drug. Saturation of these metabolising pathways could
account, at least in part, for the fall in clearance of DMXAA and the
progressive change in the pharmacokinetics with increasing dose.
Pharmacodynamic studies
There was a dose-dependent increase in plasma 5-HIAA at
DMXAA doses of 650mgm
 2 and above, which became more
marked both in extent and duration, as the dose of DMXAA
increased, as shown in Figure 3.
There was no significant increase in plasma TNF-a above
control (preinfusion) levels and no consistent dose-related
increases in plasma nitrate.
Efficacy
Of the 46 patients treated with DMXAA, 36 were evaluated for their
therapeutic response to treatment. In addition to the patient
excluded because of a protocol violation (continued tamoxifen
therapy), nine patients were either not assessed or an assessment
of all lesions was not possible.
There was one unconfirmed partial response in a patient with
locally recurrent melanoma treated at 1300mgm
 2 DMXAA. Prior
to the study, this patient had undergone surgery, chemotherapy
and hormonal but no immunotherapy or biotherapy. At 2 weeks
after completing six infusions at this dose level, there was a
reduction of more than 50% in measurable skin metastases. After 3
weeks, however, there was evidence of progressive disease and
therefore this did not qualify as a partial response.
No change was recorded as the best response in six patients
(13%) on a second tumour measurement performed after six
infusions of DMXAA. However, none of these patients were
considered for a further course because of lack of benefit.
DISCUSSION
The early clinical trials of FAA were conducted before its indirect
mechanisms of antitumour activity were identified and therefore
took no account of cytokine induction. This phase I study not only
examined the toxicity, MTD, and pharmacokinetic profile of
DMXAA, but also measured the production of TNF-a and 5-HIAA,
critical events in its antitumour activity (Philpott et al, 1995;
Baguley et al, 1997). During the course of the study, the protocol
was amended to include measurement of tumour blood flow before
and after infusion of DMXAA, since reduction in tumour blood
flow is central to its antitumour activity (Zwi et al, 1994a).
The tolerability of DMXAA was assessed at doses ranging from 6
to 4900mgm
 2. The results showed that DMXAA has a toxicity
profile unlike that of conventional chemotherapy, with a notable
absence of neutropenia, and no major cardiovascular effects. 5,6-
Dimethylxanthenone acetic acid was generally well tolerated up to
the highest dose levels, with patients experiencing the acute onset
of symptoms including nausea and visual disturbance, the
intensity and duration of which was largely dependent on dose.
As visual disturbances had previously been reported in trials of
FAA (Weiss et al, 1988; Kaye et al, 1990; Siegenthaler et al, 1992),
once visual disturbances had been noted in this trial, patients were
warned about this potential toxicity prior to therapy and found
visual symptoms to be easily tolerable. Most importantly, each
patient experienced a typical pattern of symptoms, which were the
same after each course of treatment with DMXAA and rapidly
reversible. The MTD was established at 3700mgm
 2.
This study showed that DMXAA has nonlinear (dose-depen-
dent) pharmacokinetics and is highly protein bound in humans.
Saturation of protein binding in combination with nonlinear
pharmacokinetics resulted in a rapid increase in free plasma
concentrations of DMXAA at dose levels above 650mgm
 2. As the
dose of DMXAA increased almost 10-fold from 500 to
4900mgm
 2, the free plasma concentration increased more than
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l30-fold. The rapid increase in plasma concentrations at higher
dose levels appears to correlate with increased toxicity.
There was a dose-dependent increase in the plasma concentra-
tion of 5-HIAA, the major metabolite of serotonin, at DMXAA dose
levels of 650mgm
 2 and above, a change associated with vascular
shutdown preclinically (Baguley et al, 1997; Kestell et al, 2001).
Serotonin, probably released from platelets, has been suggested as
a possible factor required for the vascular effect of DMXAA as the
serotonin inhibitor cyproheptadine reduces the degree of induced
haemorrhagic necrosis. There were no consistent dose-dependent
increases in plasma nitrate or TNF-a the other factors implicated
in the actions of DMXAA. This does not preclude an increase in
tumour TNF-a levels, which might only be detected by examining
tumour biopsies. Assessment of tumour blood flow by DCE-MRI,
which was introduced to the study as a protocol amendment, did
show a reduction in tumour blood flow at the lowest dose of
DMXAA studied by this technique (500mgm
 2) (Galbraith et al,
2002). Only 11 patients had both serial 5-HIAA and DCE-MRI
measurements and possibly because of the small numbers no
relation between 5-HIAA changes and reduction in DCE-MRI
kinetic parameters could be demonstrated. The clinically measured
antitumour response seen in one patient in this study occurred at a
dose of 1300mgm
 2 DMXAA. While it is clear that significant
pharmacodynamic effects are occurring at intermediate and well-
tolerated dose levels of DMXAA, further study is needed to assess
whether there is a clinical advantage to using higher doses that
would outweigh their greater toxicity.
Vascular targeting agents are able to induce extensive vascular
shutdown and haemorrhagic necrosis in animal tumour models,
but viable cells are often preserved in the peripheral rim and these
cells will rapidly repopulate the tumour (Hill et al, 1991, 1992,
1993; Chaplin et al, 1999). This suggests that vascular targeting
agents are unlikely to produce a clinical response when used as
sole antitumour therapy. In this study, as in the parallel phase I
study of DMXAA (Jameson et al, submitted), only a single
unconfirmed tumour response was seen. Synergistic activity of
DMXAA in combination with bioreductive cytotoxic drugs (Cliffe
et al, 1994; Lash et al, 1998), chemotherapy (notably taxanes)
(Pruijn et al, 1997; Horsman et al, 1999; Wilson and Baguley,
2000), thalidomide (Cao et al, 1999), immunotherapy (Kanwar
et al, 2001), radiotherapy (Wilson et al, 1998), and radio-
immunotherapy (Pedley et al, 1999) has been demonstrated in
animal models, and the potential of DMXAA in cancer treatment
with its novel mechanism of action is likely to lie in combination
therapy with other treatment modalities.
In conclusion, this dose-escalation study demonstrates that
DMXAA is well tolerated at doses with some effect on tumour
blood flow. Although the MTD was 3700mgm
 2, it is planned
to study more patients at lower doses to determine the lowest
dose that reliably causes blood flow reduction before starting
phase II trials. The lack of cumulative toxicity indicates that repeat
dosing should be feasible. 5,6-Dimethylxanthenone acetic acid is
a novel vascular targeting agent that should be studied further
in clinical trials, particularly as a component of combination
therapy.
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